Moderna, Inc. Share Price BOERSE MUENCHEN

Equities

0QF

US60770K1079

Biotechnology & Medical Research

Market Closed - BOERSE MUENCHEN 01:27:40 15/06/2024 am IST 5-day change 1st Jan Change
130.8 EUR -3.17% Intraday chart for Moderna, Inc. -7.39% +45.80%

Financials

Sales 2024 * 4.17B 3.89B 348B Sales 2025 * 4.84B 4.53B 405B Capitalization 53.67B 50.15B 4,482B
Net income 2024 * -2.68B -2.5B -224B Net income 2025 * -2.02B -1.88B -168B EV / Sales 2024 * 11.4 x
Net cash position 2024 * 6.25B 5.84B 522B Net cash position 2025 * 3.94B 3.68B 329B EV / Sales 2025 * 10.3 x
P/E ratio 2024 *
-19.8 x
P/E ratio 2025 *
-26.7 x
Employees 5,600
Yield 2024 *
-
Yield 2025 *
-
Free-Float 90.43%
More Fundamentals * Assessed data
Dynamic Chart
1 day-3.17%
1 week-7.39%
Current month+0.15%
1 month+8.83%
3 months+38.00%
6 months+65.91%
Current year+45.80%
More quotes
1 week
129.16
Extreme 129.16
137.98
1 month
121.90
Extreme 121.9
155.30
Current year
79.97
Extreme 79.97
155.30
1 year
64.86
Extreme 64.86
155.30
3 years
64.86
Extreme 64.86
430.05
5 years
14.22
Extreme 14.218
430.05
10 years
14.22
Extreme 14.218
430.05
More quotes
Managers TitleAgeSince
Chief Executive Officer 51 01/11/01
Director of Finance/CFO 47 06/22/06
President 48 01/13/01
Members of the board TitleAgeSince
Director/Board Member 65 01/18/01
Director/Board Member 74 01/20/01
Director/Board Member 67 11/19/11
More insiders
Date Price Change Volume
14/24/14 135.1 0.00% 12
13/24/13 135.1 -2.06% 12
12/24/12 138 0.00% 7
11/24/11 138 -1.78% 7
10/24/10 140.5 -0.57% 7

Real-time BOERSE MUENCHEN, June 15, 2024 at 01:27 am IST

More quotes
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (95.7%) ; - revenues from grants (4%); - revenues from collaboration agreements (0.3%). At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development. Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
140 USD
Average target price
145.2 USD
Spread / Average Target
+3.67%
Consensus